Relugolix

Oct 02, 2017

Myovant Sciences Announces Positive Top-line Results from Takeda's Phase 3 Study Evaluating the Efficacy and Safety of Relugolix Compared with Leuprorelin for the Treatment of Uterine Fibroids

Aug 10, 2017

Myovant Sciences Provides Corporate Update and Reports Financial Results for First Fiscal Quarter Ended June 30, 2017

Jun 29, 2017

Myovant Sciences Initiates Phase 3 Clinical Program of Relugolix in Women with Endometriosis-Associated Pain